Replies to post #67 on Neos Therapeutics, Inc. (NEOS)

[chainma1l]

$20 in a year or two. Should easily be $10+ when Cotempla hits the market. I'm looking forward to the next release of Adzenys numbers.
How come "Hydrocodone polistirex and chlorpheniramine polistirex extended-release (XR) liquid suspension" is listed under Products Overview and not Pipeline? Is it approved? That's a huge one if it is abuse deterrent.
NEOS doesn't have a unique business model, but they appear to be executing well and have a lot of opportunity.